Christian Gisselbrecht
#143,621
Most Influential Person Now
Researcher
Christian Gisselbrecht's AcademicInfluence.com Rankings
Christian Gisselbrechtbiology Degrees
Biology
#10294
World Rank
#13609
Historical Rank
Biotechnology
#142
World Rank
#144
Historical Rank
Genetics
#1078
World Rank
#1177
Historical Rank
Molecular Biology
#1486
World Rank
#1513
Historical Rank
Download Badge
Biology
Christian Gisselbrecht's Degrees
- PhD Biomedical Sciences Université Paris Cité
- Masters Biotechnology Université Paris Cité
- Bachelors Biology Université Paris Cité
Similar Degrees You Can Earn
Why Is Christian Gisselbrecht Influential?
(Suggest an Edit or Addition)Christian Gisselbrecht's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A predictive model for aggressive non-Hodgkin's lymphoma. (1993) (4400)
- CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. (2002) (2551)
- Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (1995) (2257)
- Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. (2005) (1312)
- Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. (2010) (1235)
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. (2017) (930)
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. (2006) (833)
- Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. (2009) (621)
- Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. (2004) (564)
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). (2003) (538)
- The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. (2007) (528)
- Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. (2011) (521)
- Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). (1998) (503)
- European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. (2000) (472)
- Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. (2000) (453)
- Prognostic significance of survivin expression in diffuse large B-cell lymphomas. (2000) (417)
- Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. (2003) (343)
- 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. (1980) (332)
- Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. (1997) (304)
- Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. (2010) (301)
- Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. (2008) (299)
- Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. (2008) (282)
- LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. (1989) (270)
- The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. (2011) (263)
- Original article: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen (1990) (262)
- CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. (1998) (246)
- Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. (1991) (239)
- Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. (2012) (235)
- CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. (2007) (228)
- Advances in the understanding and management of angioimmunoblastic T‐cell lymphoma (2010) (218)
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study (2016) (208)
- Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. (1994) (207)
- Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. (2002) (203)
- Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. (1993) (200)
- Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. (1993) (190)
- Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. (2006) (189)
- Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. (1995) (189)
- Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). (1993) (180)
- Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation (1994) (171)
- Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries (2003) (168)
- Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas (2006) (157)
- Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. (2012) (156)
- Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. (1999) (155)
- Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. (1998) (155)
- Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy (1993) (154)
- Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. (2006) (150)
- MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. (2012) (148)
- Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. (1998) (148)
- Expression of the bcl-2 gene product in follicular lymphoma. (1992) (142)
- Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. (2003) (142)
- Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. (2008) (141)
- Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. (1996) (136)
- AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. (2006) (135)
- Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. (2006) (134)
- Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study (2007) (134)
- Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. (2010) (127)
- Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. (1992) (124)
- Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. (2009) (122)
- Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. (1994) (121)
- High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. (2003) (119)
- Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs. (1991) (118)
- How I manage patients with relapsed/refractory diffuse large B cell lymphoma (2018) (115)
- Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. (2000) (115)
- Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. (1992) (113)
- Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. (1992) (109)
- Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. (2013) (107)
- Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (2017) (105)
- Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study (2017) (102)
- p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. (2002) (102)
- Dose intensive therapy in breast cancer. (1992) (102)
- Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression (2004) (102)
- In Vitro Effect of Cyclophosphamide Metabolites on Chromosomes of Fanconi Anaemia Patients (1980) (100)
- High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. (2012) (100)
- Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. (2006) (100)
- The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab (2008) (98)
- Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. (2002) (98)
- Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. (1997) (96)
- Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). (1990) (92)
- Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. (2007) (91)
- Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets (2015) (86)
- High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. (2007) (85)
- Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA (2011) (81)
- Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. (2006) (80)
- The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study (2019) (80)
- Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Correlation with histologic features in 36 cases. French Study Group of Pathology for HIV-Associated Tumors. (1994) (80)
- Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. (1999) (78)
- Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. (2018) (78)
- Ultrastructural lesions of bile ducts in primary biliary cirrhosis. A comparison with the lesions observed in graft versus host disease. (1981) (75)
- The impact of pre‐ and post‐transplantation positron emission tomography using 18‐fluorodeoxyglucose on poor‐prognosis lymphoma patients undergoing autologous stem cell transplantation (2007) (74)
- Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. (2007) (73)
- Impact of high-dose chemotherapy on peripheral T-cell lymphomas. (2002) (72)
- Antineoplastic agents and the liver (1980) (71)
- Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. (2012) (68)
- All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2004) (68)
- Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas. (2003) (67)
- R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study (2009) (67)
- Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. (2004) (67)
- Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. (2010) (67)
- Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. (2009) (66)
- Interleukin-2 treatment in lymphoma: a phase II multicenter study. (1994) (66)
- Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. (1997) (65)
- Image-guided core-needle biopsy of peripheral lymph nodes allows the diagnosis of lymphomas (2007) (65)
- Use of rituximab in diffuse large B‐cell lymphoma in the salvage setting (2008) (65)
- Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. (2004) (62)
- Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study (2016) (61)
- Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial (2009) (60)
- High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. (1995) (59)
- Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas. (1992) (58)
- T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. (2003) (58)
- Modern management of non‐Hodgkin lymphoma in HIV‐infected patients (2007) (58)
- Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. (2009) (54)
- (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. (2011) (54)
- Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. (2010) (53)
- Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. (2003) (52)
- Autologous stem cell transplantation in lymphoma. (2007) (52)
- Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma (2013) (52)
- High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. (2005) (49)
- Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B‐cell lymphoma (2009) (49)
- Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. (1998) (49)
- Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2006) (49)
- Treatment of low‐grade non‐Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial (1990) (48)
- Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease. (1991) (47)
- R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. (2009) (47)
- A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States (2017) (46)
- Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study (2000) (46)
- Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. (1998) (43)
- The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. (2016) (42)
- Mycosis fungoides and the Sézary syndrome. (1993) (42)
- Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas (1998) (42)
- Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA). (2000) (42)
- Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma. (1998) (41)
- Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. (2016) (40)
- Antineoplastic agents and the liver. (1980) (40)
- Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma. (2009) (40)
- Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment (2008) (39)
- Possible toxicity with the association of G-CSF and bleomycin (1994) (39)
- The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. (2019) (39)
- Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. (2009) (39)
- PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). (1991) (38)
- Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. (2010) (38)
- Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring. (1993) (38)
- Histological and ultrastructural appearance of the liver during graft-versus-host disease complicating bone marrow transplantation. (1980) (37)
- Clinical and immunological study of non‐Hodgkin T‐cell lymphomas (cutaneous and lymphoblastic lymphomas excluded) (1984) (36)
- Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. (2006) (34)
- Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT (2019) (34)
- Endobronchial presentation of Hodgkin's disease: a report of nine cases and review of the literature. (1994) (34)
- Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial. (2017) (33)
- The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. (2013) (33)
- Fluorouracil (F), adriamycin (A), and cisplatin (P) (FAP): Combination chemotherapy of advanced esophageal carcinoma (1983) (32)
- Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas. (1993) (32)
- Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: results of a SFGM-TC randomised trial (2005) (32)
- Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. (1993) (32)
- High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma (2004) (31)
- Immune reconstitution after bone-marrow transplantation. (1989) (31)
- R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma (2011) (31)
- Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. (1996) (31)
- EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. (2020) (31)
- Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? (2012) (31)
- Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins’s disease or non-Hodgkin’s lymphoma (1999) (30)
- Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies (2000) (30)
- A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma (2015) (30)
- Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells. (1996) (29)
- Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte. (1996) (29)
- Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry (1998) (29)
- Estimating late adverse events using competing risks after autologous stem‐cell transplantation in aggressive non‐Hodgkin lymphoma patients (2005) (28)
- EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma (2017) (27)
- No Role for Chemoradiotherapy When Compared with Chemotherapy Alone in Elderly Patients with Localized Low Risk Aggressive Lymphoma: Final Results of the LNH93-4 GELA Study. (2005) (27)
- Second-line treatment paradigms for diffuse large B-cell lymphomas (2009) (27)
- Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. (1992) (27)
- Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. (2007) (27)
- A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial. (2016) (26)
- Analysis of Peripheral T‐cell Lymphoma Diagnostic Workup in the United States (2017) (26)
- Combined modality in Hodgkin's disease: Comparison of six versus three courses of MOPP with clinical and surgical restaging (1984) (25)
- Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma (2021) (25)
- High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results (2009) (24)
- Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA: LNH RP 93 (1997) (24)
- Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stage I, II and IIIA). (1997) (24)
- Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL). (2005) (23)
- TREATMENT OF HIV-RELATED NON-HODGKIN'S LYMPHOMA ADAPTED TO PROGNOSTIC FACTORS. (1999) (23)
- The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. (2020) (23)
- Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review. (1993) (23)
- R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study. (2007) (23)
- Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma (2008) (22)
- The EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma. (2020) (22)
- Cutaneous type of adult T cell leukemia/lymphoma in a French West Indian woman. Clonal rearrangement of T-cell receptor beta and gamma genes and monoclonal integration of HTLV-I proviral DNA in the skin infiltrate. (1990) (22)
- Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. (2011) (22)
- A multivariate analysis of the survival of patients with aggressive lymphoma (1998) (22)
- The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. (2015) (21)
- Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate‐dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy (1990) (21)
- ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). (2018) (21)
- A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte. (1998) (21)
- How to define intermediate stage in Hodgkin's lymphoma? (2005) (21)
- EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma (2018) (21)
- Radiation-induced lung injuries: a survey by computed tomography and pulmonary function tests in 18 cases of Hodgkin's disease. (1988) (21)
- Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses (2016) (20)
- Pregnancies after high-dose chemotherapy and autologous stem cell transplantation in aggressive lymphomas. (2002) (20)
- Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry (2019) (19)
- Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma (2007) (19)
- Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients (2000) (19)
- Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. (1986) (19)
- The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia. (2019) (19)
- Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry (2019) (19)
- High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. (1998) (19)
- Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. (2009) (18)
- Monarthritis revealing non-Hodgkin's T cell lymphoma of the synovium. (1988) (18)
- Disseminated toxoplasmosis following autologous bone marrow transplantation. (1994) (18)
- A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. (2020) (18)
- Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant (2018) (18)
- Failure of phenobarbital to increase bilirubin production in the rat. (1974) (17)
- 10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma. (2009) (17)
- Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. (2009) (16)
- Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies (2016) (16)
- A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B (2010) (16)
- [Adult T-cell leukemia and non-malignant adenopathies associated with HTLV I virus. Apropos of 17 patients born in the Caribbean region and Africa]. (1990) (16)
- Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial--A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2010) (15)
- Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA) (2010) (15)
- Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) (2007) (15)
- Changes in protein C, factor VII and endothelial markers after autologous bone marrow transplantation: possible implications in the pathogenesis of veno-occlusive disease. (1993) (15)
- Long term results of the GELA study, R-CHOP vs. CHOP in elderly patients with diffuse large B-cell lymphoma. (2004) (15)
- Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients. (2001) (14)
- Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant (2011) (14)
- Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. (2000) (14)
- Residual mediastinal mass in malignant lymphoma: value of magnetic resonance imaging and gallium scan. (1993) (14)
- Diversity in antibody-based approaches to non-Hodgkin lymphoma (2010) (14)
- Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma. (2001) (14)
- Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study. (2005) (13)
- 90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory. follicular lymphoma. GELA phase II study (2007) (13)
- [Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04]. (1999) (13)
- Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients. (1993) (13)
- Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. (2014) (13)
- Improving second-line therapy in aggressive non-Hodgkin's lymphoma. (2004) (12)
- Rituximab: Enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma. (2003) (12)
- European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis (2019) (12)
- Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. (2007) (12)
- Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study (2008) (12)
- Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment (2012) (12)
- The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy (2017) (12)
- Relapses, treatments and new drugs. (2012) (11)
- The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation. (2020) (11)
- In vivo purging and relapse prevention following ASCT (2002) (11)
- High-dose therapy for indolent lymphoma. (2002) (11)
- Groupe d'Etude des Lymphomes de l'Adulte (GELA) patients with advanced-stage Hodgkin lymphoma: a study by the Long-term results and competing risk analysis of the H89 trial in (2013) (11)
- Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study (2013) (10)
- The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients). (1991) (10)
- Prognostic factors in advanced Hodgkin's disease: problems and pitfalls. Towards an international prognostic index. (1995) (10)
- Fluorouracil (F), Adriamycin (A), and cisplatin (P) (FAP): combination chemotherapy of advanced esophageal carcinoma. (1983) (10)
- Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma. (1996) (10)
- A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL) (2017) (10)
- High‐dose therapy and autologous stem‐cell transplantation can improve event‐free survival for indolent lymphoma (2007) (10)
- First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation—Final results of the AATT study. (2019) (10)
- Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) (2010) (9)
- ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia. (2008) (9)
- Autoimmune hemolytic anemia disclosing Hodgkin's disease associated with Castleman's disease. (1991) (9)
- The significance of a residual mediastinal mass following treatment for aggressive non-Hodgkin's lymphomas. (1992) (9)
- Aggressive non Hodgkin lymphoma in the elderly. A retrospective study of 72 patients with clinical features and treatment. (1990) (9)
- Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study. (2009) (9)
- Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapy. (2006) (9)
- Managing large cell lymphoma. (2006) (9)
- [Prevention of chemotherapy-induced alopecia in cancer patients by scalp hypothermia (author's transl)]. (1982) (9)
- Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. (2008) (9)
- A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma (2019) (9)
- Non-Hodgkin's lymphoma associated with human immunodeficiency virus: treatment with LNH 84 regimen in a selected group of patients. (1992) (9)
- European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (2019) (8)
- The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use. (2014) (8)
- Reducing Bureaucracy in Clinical Research: A Call for Action (2020) (8)
- Long term hematologic recovery after autologous stem cell transplantation in lymphoma patients: impact of the number of prefreeze and post-thaw CD34+ cells. (2005) (8)
- Cognitive Effects of Once Weekly (QW) Epoetin Alfa in Anemic Patients (pts) with Hematologic Malignancies Receiving Chemotherapy (CT): Interim Results of the EPOLYM Trial. (2004) (8)
- Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era (2011) (8)
- Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LNH98-B3 GELA study (2007) (8)
- Myelodysplasia after autotransplantation. (2000) (8)
- Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. (2016) (8)
- Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy (2010) (8)
- Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis (2015) (8)
- Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patients. (2001) (8)
- Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-Cell lymphoma (DLBCL) treated with R-CHOP 14 or RCHOP21: Preliminary results of the LNH03-6B randomized GELA study. (2006) (8)
- Refining the treatment of follicular lymphoma (2008) (8)
- Improving Second-Line Therapy in Aggressive Non-Hodgkin's Lymphoma. (2004) (7)
- A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL) (2020) (7)
- [Gallium-67 scintigraphy in malignant lymphoma]. (1993) (7)
- Peripheral blood stem cell CD34+ autologous transplant in relapsed follicular lymphoma. (1997) (7)
- Enrichment of peripheral blood CD34+ cells for transplantation using a fully automated immunomagnetic cell selection system and a novel octapeptide releasing agent (1999) (7)
- R-CHOP VERSUS R-FC FOLLOWED BY MAINTENANCE WITH RITUXIMAB OR IFN (2011) (7)
- Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. (2020) (7)
- Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective (2020) (7)
- Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy. (2008) (7)
- Abstracts: Heavy Metals in the Environment IV (1976) (7)
- The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. (2020) (7)
- Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study (2010) (7)
- Successful interleukin‐2 therapy of advanced cutaneous T‐cell lymphoma (1992) (7)
- FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY (2019) (7)
- New perspectives in the therapeutic approach of peripheral T-cell lymphoma (2018) (7)
- Anthracyclines in the treatment of acute nonlymphocytic leukemias. (1981) (7)
- Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease. (1990) (6)
- The Treatment of AIDS-Related Lymphoma (1992) (6)
- [Low-grade non-Hodgkin's lymphoma in the adult: new therapeutic approaches]. (1987) (6)
- Autologous bone marrow transplantation in Hodgkin's disease. (1990) (6)
- Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. (2019) (6)
- [Methotrexate-induced skin detachment]. (1992) (5)
- CONSTITUTIONAL UNCONJUGATED HYPERBILIRUBINÆMIA (1977) (5)
- Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphoma: Standard of Care After the PETAL Study? (2018) (5)
- Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry (2012) (5)
- Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B (2010) (5)
- [Hodgkin's disease. Residual histologically stable masses after chemotherapy]. (1984) (5)
- Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma. (1996) (5)
- Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). (2009) (5)
- Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL) (2014) (5)
- Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant (2010) (5)
- A PHASE-III RANDOMIZED PLACEBO-CONTROLED STUDY IN 315 PEDIATRIC AND ADULT AUTOLOGOUS OR ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH LENOGRASTIM-5 UG/KG/DAY (GLYCOSYLATED RHU-G-CSF) (1993) (5)
- A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma. (2013) (5)
- Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. (2012) (5)
- Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy (2011) (5)
- [Epidermotropic T-cell gamma/delta lymphoma]. (1993) (4)
- High Performance Liquid Chromatography of an New Antineoplastic: (1-γ diethyl amino propyl amino)-5-methyl-dipyrido [4,3-b] [3,4-f] Indole (BD 40) (1983) (4)
- Long Term Follow-up of the GELF86 French and Belgian Trials : Complete Remission after First Line Treatment with Conventional Chemotherapy in Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall Survival Compared with Partial Remission. (2008) (4)
- Alternating Chemotherapy Does Not Improve Results in Poor-prognosis Aggressive Lymphomas - Lnh87 Protocol Group-3 - a Gela Study (1993) (4)
- Chemotherapy dose intensity facilitated by use of lenograstim--implications for quality of life and survival. (1994) (4)
- European School of Oncology: management of non-Hodgkin's lymphomas: conclusions of the European School of Oncology Meeting, 1986. (1987) (4)
- Autologous stem cell transplantation (ASCT) as consolidation therapy for patients with low-intermediate (LI) risk diffuse large B-cell lymphoma (DLBCL) and overexpression of bcl2 protein. Results of the first interim analysis of the GELA trial LNH98-B2. (2004) (4)
- Futility of relapsed diffuse large B cell lymphoma transplantation? (2014) (4)
- 90yttrium Ibritumomab Tiuxetan (zevalin) Combined With Beam (z-beam) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed Or Refractory Follicular Lymphoma. a Gela Phase Ii Prospective Study (2009) (4)
- SCHOLAR-1 versus ZUMA-1: A Standardized Comparison of Outcomes in Patients (Pts) with Refractory, Aggressive Non-Hodgkin Lymphoma (rNHL) (2017) (4)
- [Influence of the granulocyte growth factor on the cost of bone marrow autografts in oncologic hematology]. (1994) (4)
- nine cases and review of the literature (2002) (4)
- Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study. (2006) (4)
- Characteristics of Refractory and Relapsing Patients with Diffuse Large B-Cell Lymphoma. (2008) (4)
- Phase I study of bisantrene in acute nonlymphoblastic leukemia. (1985) (4)
- Peripheral T cell lymphoma following angioimmunoblastic lymphadenopathy. (1987) (4)
- Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma (NHL) with the ACVBP regimen. A GELA (Groupe d'Etude des Lymphomes de l'Adulte) cohort study on 2849 patients. (2001) (4)
- Alternance of chemotherapy does not improve results in aggressive non-Hodgkin's lymphoma: A prospective randomized study on 884 patients LNH87 protocol group 3: A gela study (1996) (4)
- [Cancer of the breast: intensive treatment with bone marrow autografts]. (1989) (4)
- THERAPY OF HIV-RELATED NON-HODGKIN'S LYMPHOMA: AN EUROPEAN MULTICENTRIC RANDOMIZED STUDY IN PATIENTS STRATIFIED ACCORDING TO THEIR PROGNOSTIC FACTORS (1997) (4)
- [Non-Hodgkin lymphoma arising in a case of Waldmann's intestinal lymphangiectasis]. (1985) (4)
- Current approaches to the treatment of non-Hodgkin's lymphoma (2011) (4)
- Early Response Evaluation with 18FDG-PET Scanning, but Not Phenotypic Profile, Are Predictive of Outcome in Diffuse Large B-Cell Lymphoma. (2005) (3)
- Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3). (2009) (3)
- 182 P - Epirubicin, bleomycin, vinblastine and prednisone (EBVP) chemotherapy (CT) in combination with antiretroviral therapy and primary use of G-CSF for patients (pts) with hodgkin's disease and HIV infection (HD-HIV) (1996) (3)
- High-dose treatment with autologous stem cell transplantation versus sequential chemotherapy: the GELA experience. (2001) (3)
- The European Medicines Agency Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma (2017) (3)
- Cutaneous lymphomas of the T cell type presenting primary tumors. (1989) (3)
- Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. (2020) (3)
- Analysis of peripheral T-cell lymphoma (PTCL) subtype by race and geography using the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) dataset. (2013) (3)
- EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma (2018) (3)
- [Bone marrow transplantation in the treatment of autoimmune diseases. ISAMAIR Group]. (1999) (3)
- Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study (2016) (3)
- VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers (2017) (3)
- Intensive chemotherapy plus hematopoietic stem cells transplantation for relapsing non-Hodgkin's lymphoma: the GELA experience. (1993) (3)
- Pregnancy after autologous bone marrow transplantation for malignant lymphomas. (1994) (3)
- The European Medicines Agency Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. (2021) (3)
- EPIRUBICIN, BLEOMYCIN, VINBLASTINE AND PREDNISONE (EBVP) CHEMOTHERAPY(CT) IN COMBINATION WITH ANTIRETOVIRAL THERAPY AND PRIMARY USE OF G-CSF FOR PATIENTS (PTS) WITH HODGKIN'S DISEASE AND HIV INFECTION (HD-HIV).: 63 (1997) (3)
- Collection, cryopreservation and autologous transplantation with circulating hemopoietic stem cells in patients with multiple myeloma and lymphoma. (1990) (3)
- [Hodgkin disease with nodular lymphocytic predominance or type I (paragranuloma of Poppema-Lennert): a clinico-pathological entity. Study of 21 cases and review of the literature]. (2000) (3)
- Is Good Clinical Practice Becoming Poor Clinical Care? (2017) (3)
- Plitidepsin Is Active in Peripheral T-Cell Lymphoma (PTCL): A Subset Analysis from An Ongoing Multicenter Phase II Trial. (2008) (3)
- Clinical trials with diglycoaldehyde (NSC-118994): review and reasons for withdrawal from clinical trial. (1981) (3)
- Can we improve ABVD in Hodgkin's lymphoma? (2013) (3)
- Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. (2022) (3)
- VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. (2017) (3)
- Long-term follow-up of high-dose treatment (HDT) with autologous haematopoietic progenitor cell support in 702 patients (pts.) with follicular lymphoma (FL). An EBMT registry study. (2006) (2)
- Ofatumumab in diffuse large B cell lymphoma? (2013) (2)
- [The role of zorubicine in the treatment of acute myeloid leukemia. Evaluation of 15 years' use]. (1987) (2)
- Should we replace dexamethasone, cytarabine, and cisplatin for relapsed lymphoma? (2014) (2)
- Interim-Positron Emission Tomography with [18F]Fluorodeoxyglucose (interim-PET) Evaluation In Mediastinal Lymphoma Including Hodgkin Lymphoma (HL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL) (2010) (2)
- The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease (2021) (2)
- Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry (2018) (2)
- Effect of Lenograstim on the Cost of Autologous Bone Marrow Transplantation (1995) (2)
- 1040 Observational study for iron supplementation during Epoietin alpha biosimilar treatment of chemotherapy-induced anemia in cancer patients in oncology and haematology: The SYNERGY study (2015) (2)
- Ifosfamide salvage treatment before autologous stem cell transplantation in patients with refractory and relapsed Hodgkin's lymphoma: a GELA experience. (2003) (2)
- des Lymphomes de l'Adulte (GELA) trials angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude Clinical, biologic, and pathologic features in 157 patients with (2013) (2)
- Gene Expression Profile Associated with Survival in Patients with Diffuse Large B-Cell Lymphoma Treated by Chemotherapy and Rituximab. (2005) (2)
- MYC+ Diffuse Large B Cell Lymphomas (DLBCL) Treated in Randomized Prospective Salvage Therapy, RICE or RDHAP Followed by BEAM Plus Autologous Stem Cell Transplantation (ASCT). A BioCORAL Report (2011) (2)
- Constitutional unconjugated hyperbilirubinaemia. (1977) (2)
- Acute non-lymphocytic leukemia following FAM combination adjuvant chemotherapy for gastric and lung adenocarcinoma. (1990) (2)
- Autologous stem cell transplantation (ASCT) for elderly patients (>= 60 years) with non-hodgkin's lymphoma (NHL): An analysis based on EBMT registry. (2007) (2)
- [Comparison of the antiemetic effectiveness of high-dose corticosteroids with synacthene in nausea induced by chemotherapy: results of a randomized study]. (1989) (2)
- Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral (2019) (2)
- [Therapy of acute leukemia in the adult. Role of anthracyclines]. (1987) (2)
- Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation. (1991) (2)
- PARMA international protocol (1991) (2)
- Molecular signatures in T-cell lymphoma. (2010) (2)
- The Gene Expression Profile of Nodal T-Cell Lymphomas Identifies a Molecular Link between Angioimmunoblastic T-Cell Lymphoma (AITL) and Follicular Helper T Cells (TFH), and between CD30+ Peripheral T-Cell Lymphoma and ALK-Negative Anaplastic Large Cell Lymphoma (ALCL). (2006) (2)
- Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low–intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol (2010) (2)
- Pancreatic and hepatic plasmocytomas: an exceptional case. (1993) (2)
- Angioimmunoblastic T-Cell Lymphoma: A Clinicopathologic Study of 158 Patients Treated in GELA (Groupe d’ Etude des Lymphomes de l’ Adulte) Trials. (2006) (2)
- Diffuse Large B-Cell Lymphomas of the Waldeyer’s Ring Frequently Have a Germinal Center-Like Phenotype: A Clinico-Pathological Study of 209 Patients from the Groupe d’Etude des Lymphomes de L’Adulte (GELA). (2007) (1)
- Intensive Induction Treatment in Non-Hodgkin Lymphomas with Various Grades of Malignancy (1985) (1)
- [Aggressive lymphomas]. (1993) (1)
- 1161PA standardized comparison of outcomes in patients (pts) with refractory, aggressive non-hodgkin Lymphoma (rNHL) from the SCHOLAR-1 analysis and the ZUMA-1 study of axicabtagene ciloleucel (axi-cel) (2017) (1)
- Role of CT in the study of recurrences of Hodgkin's disease on the chest wall. Report on 12 cases. (1987) (1)
- Hodgkin's lymphoma: new treatment ideas for an old disease (2005) (1)
- [Therapy intensification with autologous transplantation in non-Hodgkin's lymphomas]. (2001) (1)
- TP53 mutations and rituximab-CHOP. (2012) (1)
- l'Adulte (GELA) trials first-line polychemotherapy within the Groupe d'Etude des Lymphomes de with NK/T-cell lymphoma : results of a Western series of 48 patients treated Expression of the granzyme B inhibitor PI9 predicts outcome in nasal (2013) (1)
- Bridging to Transplant in Diffuse Large B Cell Lymphoma (2016) (1)
- Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment. (2015) (1)
- Granulocyte colony-stimulating factor (G-CSF) to harvest mobilized circulating haematopoietic stem cells for autotransplantation. (1993) (1)
- standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Intensive conventional chemotherapy (ACVBP regimen) compared with (2009) (1)
- Rituximab plus gemcitabine and oxaliplatine (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study. (2010) (1)
- [Prolonged remissions induced by the combination vindesine, mitoxantrone, mitomycine C in metastatic breast cancers]. (1987) (1)
- The treatment of AIDS-related lymphoma. French-Italian Cooperative Study Group. (1992) (1)
- [Non-Hodgkin's lymphoma in HIV infection. A multicenter retrospective study of 21 cases]. (1990) (1)
- transplantation in aggressive lymphomas Pregnancies after high-dose chemotherapy and autologous stem cell (2012) (1)
- Chemotherapy of carcinomas of the digestive tract. (1982) (1)
- Quality of life following treatment for B-cell lymphoma (2011) (1)
- Prognostic factors for aggressive lymphoma patients treated with front-line autotransplantation after complete remission: A cohort study on 330 patients (2003) (1)
- [Hodgkin's disease in 2 human immunodeficiency virus seropositive women]. (1988) (1)
- Hodgkin's lymphoma: what is next in salvage treatment? (2003) (1)
- [Superficial adenopathy. Diagnostic orientation]. (1994) (1)
- [Monoclonal antibodies in the treatment of lymphoma]. (2002) (1)
- Pralatrexate Reverses the Trend to Progressive Resistance to Successive Systemic Treatment Regimens In Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) (2010) (1)
- [Recent data on anthracyclines]. (1987) (1)
- [Hematopoietic growth factors in practice: importance and problems]. (1994) (1)
- Second-line therapy for lymphoid neoplasms (2010) (1)
- [Lymphoma and AIDS]. (1989) (1)
- [Primary rectal malignant melanoma. A case report and review of the literature (author's transl)]. (1981) (1)
- Array CGH Analysis of Nodal T-Cell Lymphomas: Identification of Genomic Alterations Specific to Angioimmunoblastic and Unspecified Subtypes, and Correlation with Transcriptomic Data. (2007) (1)
- The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia (2021) (1)
- Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study. (2007) (1)
- T-Cell/Histiocyt e-Rich L arge B -Cell L ymphomas a nd C lassical Diffuse L arge B -Cell L ymphomas H ave S imilar O utcome A fter Chemotherapy: A M atched-Control A nalysis (2003) (1)
- The FAM regimen for gastric cancer: a progress report. (1981) (1)
- The Role of Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Waldenström’s Macroglobulinemia. (2007) (1)
- Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study (2015) (1)
- Treatment of human immunodeficiency virus-related lymphoma with risk-adapted intensive chemotherapy: Final analysis of the NHL-HIV 93 trial (2005) (1)
- Time to relapse and age-adjusted IPI have independent prognostic valve in aggressive lymphoma enrolled in the PARMA trial at first relapse (1998) (1)
- [Hodgkin's disease disclosed by acute myelofibrosis]. (1991) (0)
- Early relapses and failure to achieve complete remission are the main prognostic factors in CD20 diffuse large B-cell lymphoma (DLBCL) treated with R-ICE or R-DHAP followed by stem cell transplantation in the CORAL study : 218 (2008) (0)
- Cost study of 8 peripheral blood stem cells autologous transplantation in non-Hodgkin’s lymphoma (2000) (0)
- [Role of chemotherapy in the treatment of cancer of the testis in adults]. (1985) (0)
- Gut sterilization during bone marrow transplantation [proceedings]. (1978) (0)
- [The place of bone marrow autografts in the treatment of Hodgkin's and non-Hodgkin's lymphoma]. (1988) (0)
- Treatment of Chemotherapy-Induced Anemia Using Epoetin Alfa Biosimilar for Patients with Lymphoma and Myeloma: The Synergy Study (2015) (0)
- Autologous stem cell transplantation (ASCT) for elderly patients (>= 60 years) with non-hodgkin's lymphoma (NHL) (2007) (0)
- [Therapeutic indications in digestive localizations of non-Hodgkin's lymphoma in adults]. (1984) (0)
- [Acanthocytosis in cirrhosis. Report of four cases and review of the literature (author's transl)]. (1977) (0)
- Network German Low Grade Lymphoma Study Group ( GLSG ) and the European Mantle Cell Lymphoma (2007) (0)
- 382PSynergy between epoetin alfa biosimilar and IV iron in chemotherapy-induced anemia (2015) (0)
- [Nutrition and cancer]. (1992) (0)
- Epoetin Alfa Biosimilar Treatment for Chemotherapy-Induced Anemia in Current Oncology and Hematology Practice: An Iron Supplementation Subanalysis of the Synergy Study (2015) (0)
- 288 Treatment of advanced breast cancer by medroxyprogesterone acetate (MPA). results of a French multi-center trial (1983) (0)
- Shortened Firs t-Line High-Dose Chemotherapy for Pat ients With Poor-Prognosis Aggress ive Lymphoma (2002) (0)
- Physician attitudes to use of epoetin biosimilars in an established market. (2016) (0)
- [Therapeutic intensification and hematopoietic stem cell autotransplantation in the treatment of solid tumors in adults: principles, realization and application to the treatment of germ cell, trophoblastic, breast, ovarian and small-cell bronchial tumors. 1]. (1995) (0)
- From Stem Cell Transplantation to CAR-T Therapy in Relapse-Refractory Diffuse Large B-Cell Lymphoma (2022) (0)
- tablissement dune classification molculaire des lymphomes T priphriques par cDNA-array (2004) (0)
- Autologous bone marrow tarnsplantation (ABMT) after high-dose cyclphosphamide, mitoxantrone, alkeran (CMA) in breast cancer (1992) (0)
- Using Minitel Network and New Software Engineering Techniques for Randomized Clinical Trials Management (1989) (0)
- Acknowledgement to Referees (2005) (0)
- [The principal anticancer agents]. (1981) (0)
- Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective (2020) (0)
- No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials (2014) (0)
- Z-BEAM Transplantation (2007) (0)
- An update on90Y-ibritumomab tiuxetan in autologous stem cell transplantation (2009) (0)
- [Complete remission of a localized Burkitt-type lymphoma occurring after Hodgkin's disease]. (1985) (0)
- Peripheral T-cell lymphoma (2013) (0)
- Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study. (1987) (0)
- Prognostic value of FDG-PET/CT in Hodgkin's disease patients stage IV with bone lesions (2007) (0)
- 373PDReal-life efficacy of an epoetin alfa biosimilar in chemotherapy-induced anemia (2015) (0)
- Evidence of a Graft Versus Lymphoma (gvl) Effect in a Case of Aggressive Non-hodgkins-lymphoma (nhl) (1994) (0)
- Title: A Randomized Study of Interferon Alpha-2b Versus no Treatment as Consolidation (2013) (0)
- Challenging CD30-positive lymphomas--current challenges, new insights and future directions: joining a conversation on CD30+ lymphomas. (2014) (0)
- High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls. (2008) (0)
- [Digestive disorders induced by chemotherapeutic treatment]. (1985) (0)
- Epoetin zeta in patients with hematological malignancies with or without iron supplementation: A sub-analysis of the SYNERGY study. (2016) (0)
- Autologous BMT for post-remission therapy in adult ALL: an immunological approach. For The French Group of Therapy of Adult ALL. (1994) (0)
- Comment on Matasar et al , page 499 Ofatumumab in diffuse large B cell lymphoma ? (2013) (0)
- Management of Non-Hodgkin’s Lymphomas: Conclusions of the First Intercity Meeting, 1986 (1990) (0)
- Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma. (2003) (0)
- No advantage of chemoradiotherapy over chemotherapy alone in elderly patients with localized low risk aggressive lymphoma: results of the LNH93-4 GELA study. (2005) (0)
- Bone-marrow Transplantation Prolongs Survival After Relapse in Lymphoma Patients - Long-term Follow-up (1993) (0)
- Approaches for First-Line Therapy of Peripheral T-Cell Lymphoma (2013) (0)
- The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (2021) (0)
- Real-world use of epoetin zeta compared to guidelines for chemotherapy-induced anemia. (2016) (0)
- A revival: radioimmunotherapy in mucosa associated lymphoid tissue lymphoma (2011) (0)
- [Early post-radiation pericardial changes in Hodgkin's disease. Value of x-ray computed tomography]. (1986) (0)
- Real-world efficacy of epoetin zeta for chemotherapy-induced anemia in patients with solid tumors: A sub-analysis of the SYNERGY study. (2016) (0)
- Effect of combination chemotherapy, duration of methotrexate administration, and Patient's age on methotrexate pharmacokinetics (2004) (0)
- nine c cases a and r review o of t the l literature (1994) (0)
- Autologous Transplantation in Relapsed or Refractory Hodgkin’s Lymphoma – The Challenges (2015) (0)
- Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa (2022) (0)
- [Must the immunologic T phenotype be examined as a prognostic factor for aggressive lymphomas?]. (1993) (0)
- Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma. (1998) (0)
- Which aggressive B cell lymphoma should not be treated with RCHOP? (2020) (0)
- Can High Dose Therapy Change the Course of Low Grade Lymphoma? A Study Considering Patients as Their Own Control. (2004) (0)
- Blood 8 N O V E M B E R 2 0 1 2 I V O L U M E 1 2 0 , N U M B E R 1 9 3867 (0)
- [The role of autografts in severe or metastatic breast cancers]. (1994) (0)
- 10 Peripheral blood progenitor cells (PBPC) and treatment of non-hodgkin's lymphoma (1995) (0)
- Estimating the impact of rituximab on bcl-2-associated resistance to CHOP using competing risks in elderly patients with diffuse large B-cell lymphoma (DLBCL). (2006) (0)
- An unmet need for long-term follow-up in Hodgkin's lymphoma? (2018) (0)
- Autologous Stem Cell Transplantation in Intermediate and High Grade Lymphoma (2020) (0)
- Peripheral T / Nk Cell Lymphoma Clinic and Therapy (2004) (0)
- [Therapeutic intensification and hematopoietic stem cell autotransplantation in the treatment of solid tumors in adults. Principles, realization, and application to the treatment of germinal, trophoblastic, breast, ovarian and small-cell bronchial tumors. 2]. (1995) (0)
- Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab? (2012) (0)
- Peripheral blood stem cells (PBSC) : collections for use in autologous transplantation for lymphomas (1990) (0)
- "Pegase" program for evaluation of autologous stem cell transplantation in breast cancer. SFGM and PEGASE Group. (1996) (0)
- Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (2012) (0)
- Diffuse large B-cell lymphoma (DLBCL) of the waldeyer'ring (WR) frequently have a GC-like phenotype: a clinico-pathological study of 209 patients from the groupe d'étude des lymphomes de l'adulte (GELA). (2008) (0)
- High-Dose T herapy a nd A utologous S tem-Cell T ransplantation Versus C onventional T herapy f or P atients W ith A dvanced Hodgkin's L ymphoma R esponding t o F ront-Line T herapy (2003) (0)
- [Current advances in cancer immunotherapy (author's transl)]. (1981) (0)
- High dose therapy and autologous stem cell transplantation in first relapse for dlbcl still improves progression free survival in the rituximab era. a retrospective analysis of the ebmt-lwp (2010) (0)
- EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma (2021) (0)
- [Prognosis of cytomegalovirus infections after bone marrow transplantation]. (1979) (0)
- New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Introduction. (2009) (0)
- Proliférations à lymphocytes T (Table ronde) (1984) (0)
- [Treatment of advanced epidermoid carcinoma of the oesophagus with combined 5-fluorouracil, adriamycin and cis-platinum (FAP)]. (1982) (0)
- cell lymphoma A new prognostic index (MIPI) for patients with advanced-stage mantle (2008) (0)
- HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL SUPPORT IN FIRST LINE TREATMENT OF AGGRESSIVE NON HODGKIN LYMPHOMA: RESULTS OF AN INDIVIDUAL PATIENT DATA META-ANALYSIS (2009) (0)
- Comparison o f H igh-Dose T herapy a nd A utologous S tem-Cell Transplantation W ith C onventional T herapy f or H odgkin's Disease I nduction F ailure: A C ase-Control S tudy (1999) (0)
- Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant? (2022) (0)
- Positron emission tomography using 18-fluorodeoxyglucose in pre- and post-transplantation in lymphoma patients treated with autologous stem cell transplantation: Impact (2007) (0)
- Quality of life in 269 poor-risk diffuse large B-cell lymphoma patients treated with rituximab versus observation after front-line auto transplantation: The GELA LNH98-3 randomized trial. (2010) (0)
- The European Medicines Agency Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. (2021) (0)
- Is nivolumab an option for Hodgkin's lymphoma? (2016) (0)
- Late Events in Patients with Relapsed or Refractory Hodgkin’s Lymphoma Treated with an Autologous Stem Cell Transplantation. (2007) (0)
- Distinct Expression Patterns of microRNAs in Activated B Cell (ABC) and Germinal Center B (GC) Subtypes of Diffuse Large B Cell Lymphoma (DLBLC). (2007) (0)
- CURRENT AND FUTURE DEVELOPMENTS IN THE TREATMENT OF CD 30 + LYMPHOMAS * (2015) (0)
- Impact of Pre-Transplantation and Post-Transplantation Positron Emission Tomography (PET) Using 18-Fluorodeoxyglucose in Lymphoma Patients Treated with Autologous Stem Cell Transplantation. (2006) (0)
- Is routine bone marrow biopsy necessary in staging patients with Hodgkin disease in the PET era (2008) (0)
- [Treatment of febrile episodes in the neutropenic subject: use of the combination of amikacin-colistin-trimethoprim-sulphamethoxazole]. (1979) (0)
- [Pharmacokinetics use in anti-cancer therapy (author's transl)]. (1978) (0)
- Hodgkin ’ s lymphoma 151 IS THE NATURAL HISTORY OF HODGKIN LYMPHOMA ( HL ) CHANGING ? (2008) (0)
- Multiple Secondary Genetic Events Inducing Histologic Progression (HP) of Non-MALT Marginal Zone Lymphoma (MZL): An Integrated Genomic Analysis of Genome-Wide Copy-Number-Changes (CNC) and Transcriptomic Data. (2008) (0)
- patients at high risk of relapse candidates for intensifica- tion with HDT and ASCT. (2009) (0)
- [Late treatment related complications of Hodgkin's disease]. (1998) (0)
- [Treatment of intermediate-grade non-Hodgkin lymphoma in adults]. (1995) (0)
- [Intensive chemotherapy with autologous bone marrow transplantation: assessment and limits. What is its future?]. (1995) (0)
- New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary. (2009) (0)
- 480Patterns of failure, according to radiotherapy portals in localized non Hodgkin's lymphomas (stage I & II NHL) (1996) (0)
- lymphomas Prognostic significance of survivin expression in diffuse large B-cell (2013) (0)
- Anatomo-surgical aspects after chemotherapy for metastatic germ-cell tumors. (1985) (0)
- or R-DHAP followed by BEAM plus autologous stem cell transplantation diffuse large B-cell lymphoma is not salvaged by classical R-ICE + MYC (2012) (0)
- [Follicular lymphomas: function and expression of bcl-2 gene]. (1993) (0)
- Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study (2018) (0)
- Association of low expression of VEGF121 soluble isoform with prognostic impact and survival in patients with activated B-cell-like (ABC-like) diffuse large B-cell lymphoma (DLBCL) from the CORAL trial. (2012) (0)
- Prognostic Factors in Localized Hodgkin’s Lymphoma: How To Define Intermediate/Unfavourable Disease?. (2004) (0)
- Investigational Drugs with Activity against Non-Hodgkin’s Lymphomas (1985) (0)
- [Current advances in cancer immunotherapy (author's therapy)]. (1981) (0)
- [Residual masses after chemotherapy of non-Hodgkin's lymphoma]. (1988) (0)
- Acknowledgment of Reviewers 2021. (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Christian Gisselbrecht?
Christian Gisselbrecht is affiliated with the following schools:
